Search

High strength and low Young’s modulus is the desired combination of mechanical properties for the endoprostheses material. Metastable beta titanium alloys are promising materials for this application. In this study, four Ti-xNb-6Ta-7Zr-0.7O (wt.%) alloys were prepared where Nb content ranged from 26 to 35 wt. %. All alloys contained pure beta phase. The high oxygen content causes high microhardness (330 HV), hence also the strength, while decreasing content of Nb leads to lower electrons per atom (e/a) ratio. The e/a ratio affects the Young’s modulus which is highest (76 GPa) in Ti-35Nb-6Ta-7Zr-0.7O alloy with e/a=4.31 and the lowest (64 GPa) in Ti-26Nb-6Ta-7Zr-0.7O with e/a=4.24. Such evolution of Young’s modulus is in accordance with existing literature data, however, in comparison with other works, the Ti-26Nb-6Ta-7Zr-0.7O alloy shows double microhardness when compared to alloys with similar Young’s modulus. Therefore, the approach of using controlled oxygen content for alloy design is very promising for development of biocompatible metastable beta Ti alloy for endoprostheses production.

Founded in 1919, the Society of Biology of Strasbourg (SBS) is a learned society whose purpose is the dissemination and promotion of scientific knowledge in biology. Subsidiary of the Society of Biology, the SBS celebrated its Centenary on Wednesday, the 16th of October 2019 on the Strasbourg University campus and at the Strasbourg City Hall. This day allowed retracing the various milestones of the SBS, through its main strengths, its difficulties and its permanent goal to meet scientific and societal challenges. The common thread of this day was the transmission of knowledge related to the past, the present, but also the future. At the start of the 21st century, the SBS must continue to reinvent itself to pursue its objective of transmitting scientific knowledge in biology and beyond. Scientific talks performed by senior scientists and former SBS thesis prizes awardees, a round table, and informal discussions reflected the history and the dynamism of the SBS association. All SBS Centennial participants have set the first milestone for the SBS Bicentennial., (© Société de Biologie, 2020.)

Reversible dementia is rare and accounts for approximately 1.5% of all dementias. Systematic ancillary investigations aimed at detecting an infectious disease, an endocrine aetiology or a vitamin deficiency are rarely contributive, but remain relevant since reversible dementia may, very rarely, mimic Alzheimer-type dementia. Aetiological investigations are much better selected and contributory when they rely on a precise analysis of the clinical picture (past medical history, age of the patient, cognitive, psychiatric and behavioural symptoms, type of onset, and associated signs) and of cerebral imaging. Discovering a reversible cause of dementia does not always mean that the patient will completely recover; thus it is more appropriate to use the term "potentially reversible dementia". Finally, when the patient does not recover from dementia, systematic ancillary investigations can identify and treat concomitant reversible conditions, which in nearly 25% of dementia cases contribute to worsening the condition.

With dopaminergic systems, non dopaminergic neurotransmission probably plays a major role in parkinsonian syndromes (Multiple System Atrophy, Progressive Supranuclear Palsy, Pure Autonomic Failure, Cortical basal degeneration, Lewy Body Disease). A better understanding of the pathophysiology of these syndromes led to the development of molecules that interact with non dopaminergic systems. Thus, freezing, gait and balance disorders, dysautonomia and neuropsychiatric disorders are likely to benefit from specific treatments. However, due to methodological difficulties related to the evaluation of such molecules, controlled trials are rather rare and the results are often partial and sometimes unclear.

The practice of therapeutic trials is indispensable in the management of bronchial carcinoma if one hopes to improve the results. We have questioned 134 doctors in the Alsace region who are involved in the diagnosis and treatment of bronchial cancer. We asked how they would wish to be treated if they had a small cell cancer, and if they would agree to participate in a therapeutic trial should the occasion arise. Four different clinical situations of small cell carcinoma localised to the hemithorax were presented, illustrating current controversy on the best treatment or treatments to apply. The 4 proposed protocols were refused by 50% to 84% of the doctors questioned in different cases. The greater the level of consensus on a therapeutic treatment in a given clinical situation the greater the level of refusal to participate in a randomised protocol was. The fact that at least half of the specialist doctors questioned would refuse to be included in a current therapeutic protocol which is underway for patients in Europe leads to the suggestion that before the application for new protocols experts surrogates should give their opinion in association with ethical committee.

Using an IBM 3741 computer, the authors analysed 592 case records of patients aged over 70 years, admitted to hospital on an intensive care unit, age appears to be an important factor in determining the prognosis of numerous diseases without, however, being a criteria for rejection of admission of these patients to an intensive care unit. The fragility of these patients leads one to consider the following parameters: 1--the degree of resuscitation is assessed by quantification of the therapeutic means. As for other patients, survival varies inversely in relation to the important of the therapeutic means, but in the case of the elderly patient, there is a definite difference in the correlation mortality-therapeutic index towards aggravation, so one may determine a ceiling above which survival is not possible; 2--duration of the intensive care is very important. In most cases, the decisive point is situated on the 3rd or 4th day of care, at which time the decision to continue or stop treatment may be considered in the light of the patient's progress.

EB 51 (Trivemil) is an original fat emulsion containing L. aminoacids and glucids in its liquid phase in the following proportions: amino acids: 60 gl/l corresponding to 8,77 g of nitrogen or 250 calories, sorbitol: 100 g/l or 400 calories wheatgerm oil: 38 g/l or 350 calories. This preparation supplies 1000 per liter. Its objective is to furnish simultaneously the amino acids as well as the energy necessary for their anabolism. EB 51 was administered in 43 patients during several days at a dosage of 1000 or 1500 ml. The tolerance of the product was excellent. Its usefulness was appreciated by nitrogen balance studies as well lipid blood tests. The clearing of the plasma in practically all the cases was very good and the nitrogen saved was almost equivalent to the amount furnished. The indications, dosage and contreindications of EB 51 are detailed.

Two groups of ten patients each, staying in a Intensive Care Unit, received exclusive parenteral alimentation with different concentrations of branched chain amino acids (BCAA). Group A received studied solution containing 12 g N (852 mmol) with 41,1 p. 100 BCAA. Group B received control solution containing 18 g N (1278 mmol) with 21,1 p. 100 BCAA. Every patient received 60 nonprotein Kcal x kg-1 body weight/24 hr. The study was performed on five days. Measured parameters were: daily (D0 to D5) N balance, blood urea N and total protein and urinary alpha amine N, and after therapy (D6) amino acid levels. Results have shown no statistical significant difference between both groups. N balance became less negative during the therapy. Amino acid levels were in the normal range and alpha amine urinary elimination remained low in patients with parenteral nutrition. These results indicate that 12 g (852 mmol) N in BCAA rich solution are as efficient as 18 g (1278 mmol) N in standard solution, allowing a N sparing.